Imaging in Prostate Carcinoma-Reference-Cited by-同舟云学术

Imaging in Prostate Carcinoma

Published:2013-12 Issue:6 Volume:27 Page:1163-1187
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Zukotynski Katherine,Haider Masoom A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference147 articles.

1. American Cancer Society Website. Cancer facts and figures. Available at: http://www.cancer.org/Research/CancerFactsFigures/index. Accessed March 21, 2013.

2. Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers;Bryś;Med Oncol,2013

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment;Urologic Oncology: Seminars and Original Investigations;2020-07

2. A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy;Canadian Urological Association Journal;2020-02-24

3. The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points;Urology;2018-09

4. First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer;Clinical Nuclear Medicine;2017-01

5. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer;Clinical Nuclear Medicine;2017-01